US 6,982,323 B1
Chimeric proteins for diagnosis and treatment of diabetes
Yi Wang, Orange, Conn. (US); John Mueller, Old Lyme, Conn. (US); and Louis A. Matis, Southport, Conn. (US)
Assigned to Alexion Pharmaceuticals, Inc., Cheshire, Conn. (US)
Filed on Mar. 21, 2000, as Appl. No. 9/528,225.
Application 09/528225 is a continuation of application No. PCT/US98/27408, filed on Dec. 23, 1998.
Claims priority of provisional application 60/068648, filed on Dec. 23, 1997.
Int. Cl. C07K 14/62 (2006.01); C07K 14/435 (2006.01); A61K 38/17 (2006.01); A61K 38/28 (2006.01); A61K 38/43 (2006.01)
U.S. Cl. 530—403 8 Claims
 
1. A chimeric fusion protein comprising an amino terminus and a carboxyl terminus, wherein the protein comprises, in order, starting at the amino terminus, insulin chain B, insulin chain C and human GAD 65 peptides 115-127, 247-286, and 473-519, wherein the insulin chain B and the at least one human GAD 65 peptide(s) are covalently linked and the chimeric fusion protein is capable of eliciting a human T cell response to insulin chain B and to each of the GAD 65 peptides.